
An outbreak of new coronavirus (COVID-19) originated by SARS-CoV has reached 212 countries throughout the world. India is the second-highest populated country, so it is critical to forecasting the confirmed cases and deaths due to pandemic. To fulfil the purpose, three machine learning models Linear Regression, Multilayer Perceptron, and Sequential Minimal Optimization Regression are used. The predictive data of three geographic regions (India, Maharashtra, and Tamil Nadu) are compared with the data considered to be adequate in practice. The analysis concluded that Sequential Minimal Optimization Regression can be adopted for possible pandemic predictions such as COVID-19.
Background: Complicated intra-abdominal infections are still associated with a high risk of an unfavorable outcome. Despite the equal treatment, the mortality rates in some patients’ populations remain significant, especially when the impaired immune response is present. Aim: The object of this research is to analyze the impact of pro-inflammatory neutrophil CD64 and anti-inflammatory monocyte HLA-DR on the final outcome. Methods: We have searched in the PubMed database, the literature relating the prognostic value of two biomarkers - nCD64 and mHLA-DR in patients with complicated intra-abdominal infections and/or sepsis. Results: Eighteen original studies with 2960 patients fulfilled our inclusion criteria. The data about nCD64 that we found was contradictory, whereas low mHLA-DR expression showed good prognostic value. Conclusion : Our review showed heterogeneous data about nCD64 survival prediction. Further investigations with surgical patients exclusively are needed to evaluate its prognostic value in cIAIs. However, we observed a good prognostic performance of low mHLA-DR expression. After a validation in larger multicentre studies, mHLA-DR could be used as promising prognostic biomarker in cIAIs.
It is not unbeknownst to us that since the very onset of the COVID-19 outbreak, many patients from different age groups have suffered greatly, and in a remarkable number of cases, succumbed to their untimely demise as a result of infection with the novel coronavirus or SARS-CoV- -2. The elderly are perhaps the most vulnerable community, who stand at the pinnacle of morbidity and mortality rates due to contracting severe forms of COVID-19. Hopefully, based on the recent findings and the present evidence, there might be a number of medications that would possibly be of great prophylactic and therapeutic value to the elderly patients diagnosed with COVID-19. According to an interventional study, Thymosin α1 is arguably one such medication that has recently been indicated to be an effective therapeutic agent for inpatient management of lymphocytopenia and T cell exhaustion caused by COVID-19.
Background: Interleukin 10 (IL-10) is a powerful anti-inflammatory cytokine capable of preventing inflammatory and autoimmune diseases. Oral lichen planus (OLP) is an autoimmune, chronic, inflammatory disease with relapsing nature involving oral mucous membranes. It was prevsiouly assumed that like other autoimmune diseases, IL-10 may have a role in OLP pathogenesis, and many studies focused on that. But there are obvious controversies among IL-10 levels in OLP patients. Objective: In this review with Meta-Analysis, we attempt to assess IL-10 expression in OLP patients. Methods: The search was conducted via Pubmed, Ovid, and Google Scholar, to identify articles published up to Jun 2020. A meta-Analysis by Revman 5.3 was conducted based on serum levels of IL-10 in 313 OLPs and 203 controls. Results: With Meta-Analysis in 313 OLPs and 203 controls, the Mean difference between IL-10 in OLPs and controls was obtained as 0.26 (95% CI: -0.51-1.03), demonstrating no statistically significant difference. Conclusion: IL-10, in concert with its receptors, has a crucial role in the pathogenesis of various diseases, including inflammatory, infectious, and autoimmune diseases. Both over-expression, as well as IL-10 deficiency, have been described in oral lichen planus. With Meta-Analysis on serum IL-10 levels, it is speculated that no significant relationship exists between IL-10 and OLP pathogenesis. With respect to the importance of cytokines in the autoimmunity process, performing additional studies is of necessity to understand the association of other cytokines with OLP predisposition and its underlying pathological processes.
Interstitial lung disease, a term for a group of disorders, causes lung fibrosis, is mostly refractory to treatments and has a high death rate. After diagnosis the survival is up to 3 years but in some cases the patients live much longer. It involves a heterogenous group of lung diseases that exhibit progressive and irreversible destruction of the lung due to the formation of scars. This results in lung malfunction, disruption of gas exchange, and eventual death because of respiratory failure. The etiology of lung fibrosis is mostly unknown with a few exceptions. The major characteristics of the disease are comprised of injury of epithelial type II cells, increased apoptosis, chronic inflammation, monocytic and lymphocytic infiltration, accumulation of myofibroblasts, and inability to repair damaged tissue properly. These events result in abnormal collagen deposition and scarring. The inflammation process is mild, and the disease is primarily fibrotic driven. Immunosuppressants do not treat the disease but the evidence is evolving that both innate and acquired immune responses a well as the cytokines contribute to at least early progression of the disease. Furthermore, mediators of inflammation including cytokines are involved throughout the process of lung fibrosis. The diverse clinical outcome of the disease is due to different pattern of inflammatory markers. Nonetheless, the development of novel therapeutic strategies requires better understanding of the role of the immune response. This review highlights the role of the immune response in interstitial lung disease and considers the therapeutic strategies based on these observations. For this review several literature data sources were used to assess the role of the immune response in interstitial lung disease and to evaluate the possible therapeutic strategies for the disease.